Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 106

Results For "NAL"

8066 News Found

India committed to equitable healthcare: JP Nadda
Policy | May 20, 2026

India committed to equitable healthcare: JP Nadda

Union Health Minister highlights India’s progress in universal health coverage, digital health, AI strategy and global vaccine cooperation during plenary session in Geneva


HVS Hospitals records highest advanced clip therapy procedures in western India
Hospitals | May 20, 2026

HVS Hospitals records highest advanced clip therapy procedures in western India

The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications


360 ONE-backed Hearzap to acquire Amplifon India
Healthcare | May 20, 2026

360 ONE-backed Hearzap to acquire Amplifon India

Combined footprint expands to 420 hearing care centres across India


Bayer’s stroke drug wins fast-track review in US
Drug Approval | May 20, 2026

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats


IGI’s new drug candidate ISB 2301 to target solid tumors
Biopharma | May 20, 2026

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027


Strand Life launches advanced proteomics capabilities
Biopharma | May 19, 2026

Strand Life launches advanced proteomics capabilities

The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample


Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge
News | May 19, 2026

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels


Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial
Clinical Trials | May 19, 2026

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm


ParexelAI launched to accelerate clinical development and improve trial efficiency
Clinical Trials | May 19, 2026

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities